Syntara Limited (ASX:SNT)

Market Cap	87.71M
Revenue (ttm)	8.16M
Net Income (ttm)	-11.91M
Shares Out	1.62B
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,345,294
Average Volume	5,144,157
Open	0.0520
Previous Close	0.0510
Day's Range	0.0510 - 0.0550
52-Week Range	0.0140 - 0.0950
Beta	0.48
RSI	37.82
Earnings Date	Apr 29, 2025

About Syntara

Syntara Limited operates as a clinical-stage drug development company that focuses on blood-related cancers in Australia. The company’s lead product candidate is SNT‐5505, which is in Phase 2 trial to treat myelofibrosis, myelodysplastic syndrome, hepatocellular carcinoma, and pancreatic cancer, as well as scar prevention. It also develops SNT-4728 in Phase 2 trial for the treatment of neurodegenerative diseases comprising isolated rapid eye movement sleep behavior disorder (IRBD) and Parkinson’s disease; SNT-5382, which is a selective lysyl ox...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Employees: 21
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: SNT

Financial Performance

In 2024, Syntara's revenue was 5.76 million, a decrease of -7.51% compared to the previous year's 6.23 million. Losses were -15.14 million, 33.3% more than in 2023.